Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma by Hedrick, Erik et al.
RESEARCH ARTICLE
Nuclear Receptor 4A1 (NR4A1) as a Drug
Target for Renal Cell Adenocarcinoma
Erik Hedrick1, Syng-Ook Lee2, Gyungeun Kim3, Maen Abdelrahim4, Un-Ho Jin1,3,
Stephen Safe1,3*, Ala Abudayyeh5*
1 Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX,
United States of America, 2 Department of Food Science and Technology, Keimyung University, Daegu,
Republic of Korea, 3 Institute of Biosciences and Technology, Texas A&M Health Sciences Center, Houston,
TX, United States of America, 4 Department of Internal Medicine, Baylor College of Medicine, Houston, TX,
United States of America, 5 Department of General Internal Medicine, University of Texas MD Anderson
Cancer Center, Houston, TX, United States of America
* ssafe@cvm.tamu.edu (SS), aabudayyeh@mdanderson.org (AA)
Abstract
The orphan nuclear receptor NR4A1 exhibits pro-oncogenic activity in cancer cell lines.
NR4A1 activates mTOR signaling, regulates genes such as thioredoxin domain containing
5 and isocitrate dehydrogenase 1 that maintain low oxidative stress, and coactivates speci-
ficity protein 1 (Sp1)-regulated pro-survival and growth promoting genes. Transfection of
renal cell carcinoma (RCC) ACHN and 786-O cells with oligonucleotides that target NR4A1
results in a 40–60% decrease in cell proliferation and induction of apoptosis. Moreover,
knockdown of NR4A1 in RCC cells decreased bcl-2, survivin and epidermal growth factor
receptor expression, inhibited of mTOR signaling, induced oxidative and endoplasmic retic-
ulum stress, and decreased TXNDC5 and IDH1. We have recently demonstrated that se-
lected 1,1-bis(3'-indolyl)-1-(p-substituted phenyl)methane (C-DIM) compounds including
the p-hydroxyphenyl (DIM-C-pPhOH) and p-carboxymethyl (DIM-C-pPhCO2Me) analogs
bind NR4A1 and act as antagonists. Both DIM-C-pPhOH and DIM-C-pPhCO2Me inhibited
growth and induced apoptosis in ACHN and 786-O cells, and the functional and genomic ef-
fects of the NR4A1 antagonists were comparable to those observed after NR4A1 knock-
down. These results indicate that NR4A1 antagonists target multiple growth promoting and
pro-survival pathways in RCC cells and in tumors (xenograft) and represent a novel chemo-
therapy for treating RCC.
Introduction
Kidney cancer is a complex and heterogenous disease and clear cell renal cell adenocarcinoma
(RCC) is the most common sub-type and represents approximately 75% of renal parenchymal
tumors [1–3]. The incidence of RCC has been increasing and it is estimated that in 2013 over
65,000 new cases will be diagnosed and 13,680 kidney cancer patients will die from this disease
[4]. Early stage RCC patients with localized tumors have a good prognosis after surgical remov-
able of the primary tumor; however, approximately 30% of all patients first diagnosed with
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RCC already have metastatic disease [1]. Patients with RCC are unusually resistant to radio
and cytotoxic drug therapies compared to responses observed for other solid tumors, and im-
munotherapies have provided some limited benefits for patients with RCC metastasis [5–8].
Recent developments of targeted therapies for treating RCC have primarily focused on clinical
applications of receptor tyrosine kinase inhibitors, neutralizing antibodies against vascular en-
dothelial growth factor (VEGF) and mTOR pathway inhibitors [9–13].
Studies in this laboratory have identified 1,1-bis(3'-indolyl)-1-(p-substituted phenyl)meth-
anes (C-DIMs) as novel antineoplastic agents that bind and act as antagonists of the orphan
nuclear receptor 4A1 (NR4A1, TR3, Nur77) which exhibits pro-oncogenic activity in several
solid tumors [14–17]. NR4A1 knockdown or treatment with the p-hydroxyphenyl-derived
(DIM-C-pPhOH) NR4A1 antagonist in pancreatic, lung and colon cancer cell lines show that
NR4A1 regulates at least three pathways that are important for cancer cell proliferation and
survival (Fig 1A). NR4A1 regulates expression of pro-survival (survivin, bcl-2) and growth pro-
moting (EGFR) genes through interaction with Sp1 bound to their corresponding proximal
GC-rich promoters [14]. NR4A1 binds to and inactivates p53 and p53-regulated sestrin 2 re-
sulting in activation of mTOR. NR4A1 and wild-type p53. NR4A1 also regulates expression of
genes such as thioredoxin domain containing 5 (TXNDC5) and isocitrate dehydrogenase 1
(IDH1) to maintain low oxidative stress in cancer cells [16]. Thus, inactivation of NR4A1 by
the receptor antagonist DIM-C-pPhOH or the corresponding p-carboxymethyl analog
(DIM-C-pPhCO2Me) decreases expression of genes associated with cell proliferation and sur-
vival, induces oxidative stress, and inhibits mTOR in cancer cell lines [17]. In this study, we
show that NR4A1 is also expressed and exhibits pro-oncogenic activity in ACHN and 786-O
kidney cancer cell lines and treatment with DIM-C-pPhOH and related NR4A1 antagonists in-
hibit cell growth and mTOR signaling, induce apoptosis and cellular stress (Fig 1A), suggesting
that NR4A1 is a potential novel drug target for treating RCC patients that overexpress
this receptor.
Methods and Materials
Cell lines, antibodies, proliferation and immunofluorescence
ACHN and 786-O human kidney cancer cell lines were purchased from American Type Cul-
ture Collection (Manassas, VA). Cells were maintained 37°C in the presence of 5% CO2 in
Dulbecco’s modified Eagle’s medium/Ham’s F-12 or RPMI-1460 medium (Sigma-Aldrich,
St. Louis, MO) with 10% fetal bovine serum. Sources of the antibodies used are summarized in
Table 1. Cells were visualized under an EVOS fl, Fluorescence microscope, from Advanced Mi-
croscopy Group using a multiband filter set for FITC, rhodamine, and DAPI. The C-DIM com-
pounds were prepared as previously described [9–11]. ACHN and 786-O kidney cancer cells
(1.0 x 105 per well) were plated in 12-well plates and allowed to attach for 24 hr, and treatment
or knockdown experiments and immunofluorescence of NR4A1 was determined essentially as
described [15–17].
Annexin V staining and ROS induction
ACHN and 786-O kidney cancer cells (1.0 x 105 per well) were seeded and allowed to attach
for 24 hr. The medium was then changed to DMEM/Ham F-12 medium contained 2.5% char-
coal-stripped fetal bovine serum, and cells were treated and analyzed for Annexin V staining
essentially as described [14]. Cellular ROS levels were ascertained using the cell permeable
probe CM-H2DCFDA (5-(and-6)-chloromethyl-2'7'-dichlorodihydrofluorescein diacetate ace-
tyl ester) from Invitrogen (Grand Island, NY).
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Fig 1. NR4A1 plays a role in RCC proliferation. (A) Pathways activated by NR4A1 and targeted by NR4A1 antagonists. (B) Cells were transfected with two
different oligonucleotides targeting NR4A1 [NR4A1(1) and NR4A1(2)] and after 72 hr, the number of cells were determined as outlined in the Materials and
Methods. (C) Cells were treated with DIM-C-pPhOH and DIM-C-pPhCO2Me and cell numbers were determined after treatment for 24 hr. (D) Cells were
transfected with NBRE3-luc and 40 ng FLAG-NR4A1, treated with DMSO, DIM-C-pPhOH (20 μM) and DIM-C-pPhCO2Me (15 μM), and luciferase activity
was determined as described [17]. (E) Cells were transfected with siCtl (non-specific) or siNR4A1 and treated with DIM-C-pPhOH and DIM-C-pPhCO2Me
and cell numbers were determined. siNR4A1 alone decreased cell proliferation as indicated in (B) and this value was set at 100% to determine the effects of
C-DIMs in cells after loss of NR4A1. (F) Athymic nude mice bearing ACHN cells as xenografts were treated with 30 mg/kg/d DIM-C-pPhOH and tumor
volumes were determined. Results (C—E) are means ± SE for at least 3 separate determinations and significantly (p < 0.05) decreased growth/volume is
indicated (*). Significant (p < 0.05) attenuation of C-DIM-induced growth or luciferase activity or after transfection with siNR4A1 is also indicated (**).
doi:10.1371/journal.pone.0128308.g001
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Western blot analysis
Cells were seeded and subsequently treated with varying concentrations of DIM-C-pPhOH or
DIM-C-pPhCO2Me for 24 hr or transfected with 100 nM siNR4A1 for 72 hr, and whole cell ly-
sates were analyzed by western blot analysis essentially as described using β-actin as the loading
control [14–17].
Small interfering RNA interference and transactivation assays
Knockdown of NR4A1 in ACHN and 786-O cells was carried out using Lipofectamine 2000 re-
agent according to the manufacture's protocol. Small inhibitory RNAs and GL2 (non-specific
oligonucleotide) were prepared or purchased from Sigma-Aldrich (St. Louis MO), and siRNA
complexes used in the study are as follows: siGL2-5', CGU ACG CGG AAU ACU UCG A;
siNR4A1 (1)-SASI_Hs02_00333289; siNR4A1 (2)-SASI_Hs01_00182072. ACHN RCC cells
were plated on 12-well plates at 5 x 104 cells per well in DMEM supplemented with 2.5% char-
coal-stripped FBS. After 24 hr, various amounts of DNA [NBRE3-luc (400 ng), FLAG-NR4A1
(40 ng)] were cotransfected into each well by Lipofectamine 2000 reagent (Invitrogen, Carls-
bad, CA) according to the manufacturer's protocol. After 6 hr of transfection, cells were treated
with 2.5% stripped DMEM containing either DMSO, DIM-C-pPhOH (20 μM) or DIM-C-
pPhCO2Me (15 μM) for 18 hr. Cells were then analyzed for luciferase activity as previously de-
scribed [17].
Ethics Statement
Animal Care and Maintenance: The Animal Use Protocol (#IACUC 2013–0251) was approved
by the Texas A&MUniversity Institutional Animal Care and Use Committee (IACUC). Mice
were housed in the Laboratory Animal Resources and Research Facility approved by the Texas
A&MUniversity IACUC at Texas A&M University, College Station, TX, and were attended by
an animal care group and veterinarian. Comfort: Necessary steps were taken to minimize the
pain and discomfort of all animals utilized in these studies. A scruff hold or gentle manual re-
straint was utilized to restrain mice for all procedures. Euthanasia: The mice were euthanized
by asphyxiation (inhalation of CO2 in a small chamber). This method is consistent with recom-
mendations of the Panel of Euthanasia of the American Veterinary Medical Association.
Orthotopic xenograft model
Male athymic nude mice (Foxn1nu, aged 6–7 weeks) were purchased from Harlan (Indianapo-
lis, IN) and housed under specific pathogen-free conditions. ACHN cells (107 cells/150 μl) in
Matrigel were injected into the flanks of individual mice (6 per group) and after 7 days when
Table 1. Antibodies and sources.
Antibodies Sources
Sp1 Millipore (Temecula, CA)
Sestrin 2 (SESN2), bcl2, CHOP, ATF4, IDH1, EGFR Santa Cruz Biotech (Santa
Cruz, CA)
Nur77 (D63C5)XP, caspase 3, cleaved poly (ADP)ribose polymerase
(c-PARP), phospho-mTOR, mTOR, phospho-AMPKα, AMPKα,
phospho-p70S6K, p70S6K, phospho-S6RP, S6RP, phospho-4EBP1,
4EBP1, and survivin
Cell Signaling Technologies
(Danvers, MA)
TXNDC5 Genetex (Irvine, CA)
Phospho-PERK Biolegend (San Diego, CA)
doi:10.1371/journal.pone.0128308.t001
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tumors were palpable, mice were randomized into two groups and dosed by oral gavage with
either corn oil or DIM-C-pPhOH (30 mg/kg/day) for 50 days. The mice were weighed, and
tumor size was measured twice a week with calipers to permit calculation of tumor volumes,
V×L×W2/2, where L and W were length and width. Tumor lysates were obtained and analyzed
for protein expression by western blots.
Statistical analysis
Statistical significance of differences between the treatment groups was determined by stu-
dent’s t test. The results are expressed as means with error bars representing 95% confidence
intervals for 3 experiments for each group unless otherwise indicated, and a P value less than
0.05 was considered statistically significant. All statistical tests were 2-sided.
Results
NR4A1 antagonists inhibit RCC cell proliferation and induce apoptosis
Fig 1A summarizes the growth-promoting and survival pathways that can be targeted by
NR4A1 antagonists in lung, pancreatic and colon cancer cells [14–17], and this study investi-
gates these pathways in RCC cells and the role of C-DIM/NR4A1 antagonists as inhibitors of
these pathways. ACHN and 786-O RCC cell lines are p53-positive and mutant cell lines, re-
spectively, and in cells transfected with two different oligonucleotides that target NR4A1
(siNR4A1), there was a significant 50–60% decrease in proliferation of both cell lines (Fig 1B).
Moreover, treatment of these cells with 0–20 μM of the NR4A1 antagonists DIM-C-pPhOH or
DIM-C-pPhCO2Me also significantly decreased cell proliferation (Fig 1C). IC50 values for both
compounds in ACHN cells were 13.6 and 11.7 μM, respectively, and in 786-O cells the values
were 13.0 and 13.4 μM, respectively. ACHN cells were transfected with an NBRE-luc construct
containing 3 monomer binding sites and both DIM-C-pPhOH and DIM-C-pPhCO2Me signif-
icantly decreased luciferase activity (Fig 1D) as previously described in colon cancer cells [17],
demonstrating NR4A1 antagonist activity in this transactivation assay. The growth inhibitory
effects of DIM-C-pPhOH and DIM-C-pPhCO2Me in ACHN and 786-O cells were significant-
ly decreased after knockdown of NR4A1 by RNAi, thus demonstrating a role for NR4A1 in
mediating the growth inhibitory effects of C-DIM/NR4A1 antagonists (Fig 1E). Moreover,
treatment of athymic nude mice bearing ACHN cells as xenografts with DIM-C-pPhOH
(30 mg/kg/d) for 50 days also resulted in a significant inhibition of tumor growth (Fig 1F)
and complemented results of the in vitro studies. Thus, both knockdown of NR4A1 by RNAi
or treatment with C-DIM/NR4A1 antagonists inhibited RCC cell and tumor growth. Transfec-
tion of ACHN and 786-O cells with two different siNR4A1 oligonucleotides also increased
Annexin V staining (Fig 2A and 2B) which is a marker of apoptosis. We also observed that
both DIM-C-pPhOH and DIM-C-pPHCO2Me induced Annexin V staining in ACHN and
786-O cells (Fig 2C and 2D, respectively), confirming that C-DIM/NR4A1 antagonists induce
apoptosis in RCC cell lines. Moreover, in S1 Fig, we also show that siNR4A1 and C-DIM/
NR4A1 antagonists also induce cleavage of caspases 7 and 8 in ACHN and 786-O cells.
Previous studies show that many apoptosis inducers that act through NR4A1 induce nuclear
export of the receptor which subsequently forms a pro-apoptotic complex with the mitochon-
drial bcl-2 protein [18–20]. In contrast, our studies show that C-DIMs act through nuclear
NR4A1 in cancer cells [14–17]. ACHN and 786-O cells were treated with DIM-C-pPhOH and
DIM-C-pPHCO2Me and after 24 hr, cells were stained with NR4A1 antibodies and DAP1 and
the results show that DAP1 and the NR4A1 immunostaining were co-localized in the nucleus,
demonstrating that the C-DIM/NR4A1 antagonists act through the nuclear receptor (Fig 3).
Inhibition of Renal Cell Adenocarcinoma by NR4A1 Antagonists
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Sp-regulated survival genes
Previous studies showed that NR4A1 in combination with p300 activated Sp-regulated genes
such as survivin, bcl-2 and EGFR in cancer cells [14–17]. Transfection of ACHN and 786-O
Fig 2. NR4A1 knockdown and C-DIM/NR4A1 antagonists induce apoptosis in RCC cells. ACHN (A) or 786-O (B) cells were transfected with siNR4A1
(1) and siNR4A1(2) and Annexin V staining was determined as outlined in the Materials and Methods. ACHN (C) and 786-O (D) cells were treated with 20 μM
DIM-C-pPhOH or DIM-C-pPhCO2Me for 24 hr and Annexin V staining was determined. Results are means ± SE for 3 replicated determinations and
significant (p<0.05) induction of Annexin V staining is indicated (*).
doi:10.1371/journal.pone.0128308.g002
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cells with siNR4A1 decreased expression of survivin, bcl-2 and EGFR and this was accompa-
nied by increased PARP cleavage (primarily in ACHN cells), a marker of apoptosis (Fig 4).
Fig 3. C-DIM/NR4A1 antagonists target nuclear NR4A1. ACHN (A) and 786-O (B) cells were treated with
20 μMDIM-C-pPhOH and DIM-C-pPhCO2Me. Cells were immunostained with NR4A1 antibodies or DAPI
and images merged as outlined in the Materials and Methods.
doi:10.1371/journal.pone.0128308.g003
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Similar results were observed in both RCC cell lines after treatment with DIM-C-pPhOH (Fig
4B) or DIM-C-pPhCO2Me (Fig 4C), confirming that the NR4A1 antagonists inhibited
NR4A1-regulated expression of survivin, bcl-2 and EGFR in ACHN and 786-O cells as previ-
ously reported in pancreatic, lung and colon cancers [14–17]. Thus, cells transfected with
siNR4A1 or treated with C-DIM/NR4A1 antagonists induced multiple markers of apoptosis
including increased Annexin V staining, cleavage of caspases 3, 7, 8 and PARP and this was ac-
companied by downregulation of the anti-apoptotic genes survivin and bcl-2. In addition, we
also observed decreased expression of survivin, bcl-2, EGFR and induced PARP cleavage in
tumor lysates from nude mice bearing ACHN cells as a xenograft and treated with DIM-C-
pPhOH (30 mg/kg/d) (Fig 4D).
siNR4A1 and C-DIM/NR4A1 antagonist induce stress in RCC cells
It has been shown that NR4A1 maintains low levels of stress in cancer cells by regulating ex-
pression of TXNDC5 and IDH1 (Fig 1A) that in turn maintain high levels of cellular reducing
agents [16, 17]. Transfection of ACHN and 786-O cells with siNR4A1 decreased expression of
TXNDC5 and IDH1 in both cell lines and this was accompanied by increased expression of
CHOP, ATF4 and phospho-PERK which are markers of ER stress (Fig 5A). Treatment of
ACHN and 786-O cells with DIM-C-pPhOH (Fig 5B) or DIM-C-pPhCO2Me (Fig 5C) also de-
creased expression of TXNDC5 and IDH1 and induced markers of ER stress (CHOP, ATF4
and p-PERK). Moreover, siNR4A or treatment with the C-DIM/NR4A1 antagonists also in-
duced ROS as determined using the cell permeant probe CM-H2DCFCA (Fig 5D). In addition,
DIM-C-pPhOH (30 mg/kg/d) also decreased expression of TXNDC5 and IDH-1 and induced
CHOP expression in tumors from athymic nude mouse xenografts (Fig 5E), demonstrating
that C-DIM/NR4A1 antagonists-dependent inhibition of RCC cell and tumor growth is due, in
part, to induction of stress (Fig 1A).
siNR4A1 and C-DIM/NR4A1 antagonists inhibit mTOR
NR4A1 binds and inactivates p53 [21], and treatment with siNR4A1 or C-DIM/NR4A1 antag-
onists results in p53-dependent induction of sestrin 2 which activates AMPKα and inhibits
mTOR [15, 17]. Knockdown of NR4A1 by RNAi in ACHN cells that express wild-type p53 re-
sulted in the induction of sestrin 2, activation of AMPKα, and inhibition of phospho-mTOR;
this was also accompanied by decreased activation/phosphorylation of mTOR-regulated
p70S6K, S6RP and 4EBP1 (Fig 6A). Treatment of ACHN cells with the NR4A1 antagonists
DIM-C-pPhOH (Fig 6B) and DIM-C-pPhCO2Me (Fig 6C) also induced sestrin 2, activated
AMPKα and inhibited activation of mTOR and downstream kinases and these results are con-
sistent with previous studies in other cancer cells expressing wild-type p53 [15, 17]. The 786-O
cell line expresses a mutant p53; however, transfection of these cells with siNR4A1 also resulted
in the induction of sestrin 2 and inactivation of mTOR and mTOR signaling (Fig 7A). More-
over, similar results were observed after treatment of 786-O cells with the NR4A1 antagonists
DIM-C-pPhOH (Fig 7B) and DIM-C-pPhCO2Me (Fig 7C). It has previously been reported
that sestrin 2 is induced by other factors including oxidative stress [22], and Fig 7D shows that
induction of sestrin 2 by siNR4A1, DIM-C-pPhOH and DIM-C-pPhCO2Me was attenuated
Fig 4. NR4A1 plays a role in expression of Sp-regulated growth promoting and survival genes. (A) Cells were transfected with siNR4A1 and whole cell
lysates were analyzed by western blots as outlined in the Materials and Methods. Cells were treated with DIM-C-pPhOH (B) or DIM-C-pPhCO2Me (C) and
after 24 hr, whole cell lysates were analyzed by western blots. (D) Western blot analysis of tumor lysates from athymic nude mice bearing ACHN xenografts
and treated with vehicle (control) or DIM-C-pPhOH (30 mg/kg/d) was also determined. Band intensities were quantitated relative to β-actin (means ± SE) and
significantly decreased staining intensities are indicated (*; p<0.05).
doi:10.1371/journal.pone.0128308.g004
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Fig 5. siNR4A1 and C-DIM/NR4A1 antagonists induce stress in RCC cells.Cells were transfected with siNR4A1 (A) or treated with DIM-C-pPhOH (B) or
DIM-C-pPhCO2Me (C) and whole cell lysates were analyzed by western blots. (D) After treatment of cells as described in (A)—(C), ROS was measured
using the cell permeant CM-H2DCFDA probe as outlined in the Materials and Methods. Significant induction (p<0.05) of ROS is indicated (*). (E) Tumor
lysates from athymic nude mice bearing ACHN cells as xenografts and treated with vehicle control or DIM-C-pPhCO2Me were analyzed by western blots and
individual bands were quantitated (relative to β-actin). Significant (p<0.05) induction of ROS is indicated (*).
doi:10.1371/journal.pone.0128308.g005
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after cotreatment with the antioxidant glutathione (GSH). Thus, induction of ROS by NR4A1
antagonist-mediated downregulation of TXNDC5 and IDH1 also results in the induction of
sestrin 2 in cells expressing mutant p53, suggesting that NR4A1 antagonists inhibit mTOR by
both p53-dependent and-independent induction of sestrin2. These studies demonstrate that
NR4A1 is a target for NR4A1 antagonists in RCC cells; this leads to inhibition of several
NR4A1-regulated pro-oncogenic pathways (Fig 1A) including mTOR and these results are
comparable to those observed in pancreatic, lung and colon cancer cells and tumors [14–17].
Discussion
NR4A receptors are immediate-early genes that are induced by diverse stressors in multiple tis-
sues/cell lines and these receptors are important for maintaining cellular homeostasis [23, 24].
The function of NR4A1 in cancer cells has also been extensively investigated and in solid tu-
mors, there is evidence that this receptor exhibits unique functions that are dependent on its
subcellular location [25–27]. NR4A1 is a nuclear receptor; however, treatment of some cancer
cell lines with apoptosis-inducing agents results in the induction and nuclear export of NR4A1
which associates with mitochondrial bcl-2 to form a pro-apoptotic complex [18–20, 25]. Thus,
mitochondrial NR4A1 exhibits tumor suppressor-like activity, and both paclitaxel and peptide
mimetics of NR4A1 that bind bcl-2 also activate apoptosis in cancer cells [20, 28]. In contrast,
results of RNAi studies suggest that nuclear NR4A1 is pro-oncogenic and plays a role in cancer
cell proliferation and survival, and studies in this laboratory have identified at least three path-
ways and associated genes that contribute to the functions of NR4A1 in cancer cells (Fig 1A).
Thus, NR4A1 is unique among orphan nuclear receptors, and the observed pro-oncogenic or
tumor suppressor-like activity is dependent on the subcellular location of the receptor. Several
different structural classes of ligands bind NR4A1 and these include cytosporone B and related
analogs [29, 30], C-DIMs [17], ethyl 2-[2,3,4-trimethoxy-6-(1-octanoyl)phenyl]acetate
(TMPA) [31], and 1-(3,4,5-trihydroxyphenyl)nonan-1-one [32]. Cytosporone B and related
compounds and 1-(3,4,5-trihydroxyphenyl)nonan-1-one induce nuclear export of NR4A1 and
TMPA antagonizes nuclear NR4A1-LKB1 interactions but does not affect NR4A1-dependent
transactivation. In contrast, our previous studies in pancreatic, lung and colon cancer cells
show that C-DIM/NR4A1 antagonists act on nuclear NR4A1 and do not induce nuclear export
of the receptor [confirmed in RCC cells (Fig 3)] and these compounds also decrease NR4A1-
dependent transactivation [14–17].
Kidney injury can induce NR4A1 expression in non-tumor tissue, and one study reported
the NR4A1 was expressed in 786-O cells and NR4A1 mRNA was more highly expressed in tu-
mors from patients with RCC compared to surrounding non-tumor tissue [33–35]. Currently,
we are accumulating tumors from kidney cancer patients to investigate the tumor-type specific
expression and prognostic significance of NR4A1. We further investigated the pro-oncogenic
functions of NR4A1 by RNAi and compared the results with that observed after treatment of
ACHN or 786-O cells with two prototypical NR4A1 antagonists, DIM-C-pPhOH and DIM-C-
pPhCO2Me. Both NR4A1 knockdown and the NR4A1 antagonists inhibited ACHN and
786-O cell proliferation and transactivation, and DIM-C-pPhOH also inhibited tumor growth
in athymic nude mice bearing ACHN cells as xenografts (Fig 1) and siNR4A1 and NR4A1 an-
tagonists also induced apoptosis in these cell lines (Fig 2). These effects are comparable to
Fig 6. siNR4A1 and NR4A1 antagonist inhibit mTOR in ACHN cells.Cells were transfected with siNR4A1
(A) and treated with DIMI-C-pPhOH (B) and DIM-C-pPhCO2Me (C), and whole cell lysates were analyzed by
western blots as outlined in the Materials and Methods.
doi:10.1371/journal.pone.0128308.g006
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Fig 7. siNR4A1 and NR4A1 antagonist inhibit mTOR in 786-O cells. Cells were transfected with siNR4A1 (A) and treated with DIMI-C-pPhOH (B) and
DIM-C-pPhCO2Me (C), and whole cell lysates were analyzed by western blots as outlined in the Materials and Methods. (D) Induction of sestrin 2 by western
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previous studies in pancreatic, lung and colon cancer cell lines [14–17], suggesting the potential
therapeutic potential for C-DIMs in treating RCC in patients that overexpress NR4A1.
Fig 1A illustrates three pro-oncogenic pathways and related genes that are regulated by
NR4A1 in pancreatic, lung and colon cancer cell lines, and we have also observed these
NR4A1-dependent response/pathways in other cancer cell lines (data not shown). NR4A1 in
combination with p300 coactivates survivin and other Sp1-regulated genes [14], and results in
Fig 4 show that survivin, bcl-2 and the EGFR were regulated by NR4A1 in RCC cells. All three
of these Sp-regulated genes play a role in cancer cell growth and survival and some studies
show that expression of survivin, EGFR and bcl-2 are negative prognostic factors for patients
with RCC [36–41]. Thus, NR4A1 regulation of these genes in RCC contributes to the tumor
phenotype, and inhibition of these genes by C-DIM/NR4A1 antagonists in RCC cells and tu-
mors (Fig 4) is an important component of their antineoplastic activity.
A second NR4A1-regulated pathway in cancer cells is associated with regulation of genes
such as TXNDC5 and IDH1 that maintain high levels of redox equivalents and decrease intra-
cellular stress [16]. Knockdown of NR4A1 (and NR4A1 antagonists) decreases TXNDC5 and
IDH1 and induced ROS and other stress responses in ACHN and 786-O cells (Fig 5), suggest-
ing that NR4A1 also maintains levels of stress that facilitate RCC growth and survival. The
functions of TXNDC5 and IDH1 have not been characterized in RCC and it is also possible
that NR4A1 regulates other similar genes and this is currently being investigated. Since previ-
ous studies show that other ROS-inducing antineoplastic agents inhibit growth and survival of
RCC [42, 43], the induction of ROS by C-DIM/NR4A1 antagonists contributed to the antican-
cer activity of these compounds.
mTOR inhibitors are currently in clinical trials for treating RCC [9–13], and our previous
studies showed that in colon and lung cancer cells expressing wild-type p53, NR4A1 inhibits
p53 activity and p53-dependent inhibition of the mTOR pathway [15]. However, treatment
with C-DIM/NR4A1 antagonists or transfection with siNR4A1 activates p53 which in turn in-
creases expression of sestrin 2 resulting in activation of AMPKα and inhibition of mTOR [15,
17]. These same effects were observed in ACHN cells that express wild-type p53, demonstrat-
ing that C-DIM/NR4A1 antagonists represent a novel class of mTOR inhibitors with clinical
potential for treating RCC patients expressing NR4A1 and wild-type p53 (Fig 6). Surprisingly,
we also observed similar results in 786-O cells that express a mutant p53, and this response was
attenuated by cotreatment with glutathione. Sestrin 2 can be induced by oxidative stress [22]
and since NR4A1 knockdown and NR4A1 antagonists induce ROS (Fig 5), this represents a
second NR4A1-mediated p53-independent pathway that can be targeted by NR4A1 antago-
nists to inhibit mTOR.
In summary, our results show that NR4A1 is pro-oncogenic in RCC and regulates at least
three pathways (Fig 1A) important for cell proliferation and survival, and these can be targeted
by C-DIM/NR4A1 antagonists. Our current studies are focused on further investigating the
functional responses and molecular pathways regulated by NR4A1 in RCC and identifying
RCC patient sub-types that overexpress NR4A1 and are potential candidates for clinical appli-
cations of C-DIM/NR4A1 antagonists.
Supporting Information
S1 Fig. Induction of apoptosis. Cells were transfected with siNR4A1 oligonucleotides (A, B)
(17) or treated with DIM-C-pPhOH and DIM-C-pPhCO2Me (C, D), and whole cell lysates
blots was determined in 786-O cells treated with DIM-C-pPhOH and DIM-C-pPhCO2Me or transfected with siNR4A1 in the presence or absence of 5 mM
GSH.
doi:10.1371/journal.pone.0128308.g007
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were analyzed by Western blots as described in the Materials and Methods.
(PDF)
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